Skip to content

Minoxidil in Transmen

Efficacy and Safety of Topical 3% Minoxidil for Facial Hair Enhancement in Transmen: A Randomized, Double-blind, Placebo-controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220205004
Enrollment
80
Registered
2022-02-05
Start date
2022-02-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topical 3% minoxidil for facial hair enhancement in transmen Facial hair, transmen, minoxidil

Interventions

topical 3% Minoxidil applied on beard and mustach area for 3 months,Vehicle placebo applied on beard and mustache area for 3 months
Experimental Drug,Placebo Comparator Drug
3% Minoxidil,Placebo

Sponsors

Division of Dermatology, Department for Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Transmen 2. Age 18 years and above 3. Be able to follow the protocol 4. Given consent to be in the study

Exclusion criteria

Exclusion criteria: 1. Candidate has acute or chronic illnesses that affect hair growth 2. Candidate has scar on study area 3. Candidate has undergone facial LASER treatment within 3 months 4. Candidate has used hair removal product within 3 months 5. Candidate has history of adverse reaction to topical minoxidil 6. Candidate request to withdraw from the protocol

Design outcomes

Primary

MeasureTime frame
Facial hair diameter and density 3 months Hair count

Secondary

MeasureTime frame
Adverse events 3 months Questionaire,Satisfaction 3 months Questionaire

Countries

Thailand

Contacts

Public ContactKantarat Wattanawinitchai

Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University

kantarat@g.swu.ac.th022011141

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026